bioAffinity Technologies to Participate in the H.C. Wainwright Global Investment Conference
07 Settembre 2023 - 2:00PM
Business Wire
bioAffinity Technologies, Inc. (Nasdaq: BIAF;
BIAFW), a biotechnology company addressing the need for
noninvasive detection of early-stage lung cancer, today announced
that Maria Zannes, President and CEO, will present a corporate
update and hold meetings with institutional investors during the
H.C. Wainwright 25th Annual Global Investment Conference being held
September 11-13, 2023.
Institutional investors interested in arranging a meeting with
bioAffinity Technologies management can register to attend the
conference virtually or in-person at the Lotte New York Palace
Hotel or contact Tirth Patel at LHA at tpatel@lhai.com.
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. addresses the need for
noninvasive diagnosis of early-stage cancer and diseases of the
lung, and targeted cancer treatment. The Company’s first product,
CyPath® Lung, is a noninvasive test that has shown high sensitivity
and specificity for the detection of early-stage lung cancer.
OncoSelect® Therapeutics, LLC, a subsidiary of bioAffinity
Technologies, is advancing its discoveries shown in vitro to kill
cancer cells without harm to normal cells. Research and
optimization of the Company’s platform technologies are conducted
in its laboratories at The University of Texas at San Antonio. For
more information, visit www.bioaffinitytech.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230907441683/en/
bioAffinity Technologies Julie Anne Overton Director of
Communications jao@bioaffinitytech.com
LHA Investor Relations Tirth T. Patel tpatel@lhai.com
Grafico Azioni bioAffinity Technologies (NASDAQ:BIAFW)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni bioAffinity Technologies (NASDAQ:BIAFW)
Storico
Da Set 2023 a Set 2024